Emergent BioSolutions (EBS) Tops Q4 EPS by 4c, Beats on Revenues; Offers FY18 Revenues Above Consensus

Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.74, $0.04 better than the analyst estimate of $0.70. Revenue for the quarter came in at $193.8 million versus the consensus estimate of $188.95 million.

For Q4 2017, adjusted net income, a non-GAAP measure, was $37.8 million, or $0.74 per diluted share, versus $36.6 million, or $0.74 per diluted share, in 2016. See “Reconciliation of Net Income to Adjusted Net Income and EBITDA” for a definition of terms and a reconciliation table.

2018 Financial Forecast:

• Total revenue of $715 to $755 million
• Pre-Tax income of $120 to $140 million
• Net income of $95 to $110 million
• Adjusted net income of $110 to $125 million (2)
• EBITDA of $175 to $190 million (2)

GUIDANCE:

Emergent BioSolutions sees FY2018 revenue of $715-755 million, versus the consensus of $706 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• RH (RH) Tops Q1 EPS by 12c
• Cracker Barrel (CBRL) Tops Q3 EPS by 71c
• Stitch Fix (SFIX) Tops Q3 EPS by 4c, Offers Guidance